Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | SVP, FINANCE, CHIEF ACCT OFFCR | September 11, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date September 11, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 80,754 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Exercise / conversion · Acquired 5,000 · Balance 80,754 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2031-04-13 | Direct | 33,589 |
Reported balance
After 2026-09-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-11 · Exercise / conversion · Disposed 5,000 · Balance 33,589 F1: 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 14, 2026 20:28 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001861684-26-000006 · form4-09142026_080921.xml · derivative · entry 2 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,589 Underlying: Class A Common Stock · 5,000 shares Expires 2031-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 11, 2026 Filed Sep 14, 2026 20:28 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 5,000 | $3.94 | $19,698.00 |
DisclosureSEC source: 0001861684-26-000006 · form4-09142026_080921.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 18:52 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001861684-26-000005 · form4-03162026_100309.xml · derivative · entry 2 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,589 Underlying: Class A Common Stock · 10,000 shares Expires 2031-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 18:52 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 10,000 | $3.94 | $39,396.00 |
DisclosureSEC source: 0001861684-26-000005 · form4-03162026_100309.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,032 shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 20:00 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 3,117 | $41.98 | $130,863.82 |
DisclosureSEC source: 0001861684-26-000004 · form4-02262026_010213.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,722 F1 · date: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. F2 · kind: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 20:00 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $42.74 | $0.00 |
DisclosureSEC source: 0001861684-26-000002 · form4-02062026_080213.xml · derivative · entry 2 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2036-02-03 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 20:00 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001861684-26-000002 · form4-02062026_080213.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,839 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 20:57 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001193125-25-280792 · ownership.xml · derivative · entry 3 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,589 Underlying: Class A Common Stock · 10,000 shares Expires 2031-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vest on March 9, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 20:57 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 10,000 | $3.94 | $39,396.00 |
DisclosureSEC source: 0001193125-25-280792 · ownership.xml · nonDerivative · entry 2 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 20:57 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 15,000 | $29.06 | $435,874.50 |
DisclosureSEC source: 0001193125-25-280792 · ownership.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,839 F1 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $29.17, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 893 ordinary shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 16:13 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 21,500 | $0.00 Strike: $29.18 | $0.00 |
DisclosureSEC source: 0001415889-25-004851 · form4-02202025_090211.xml · derivative · entry 2 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Class A Common Stock · 21,500 shares Expires 2035-02-17 F2 · derivative.exercise_date: 1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 16:13 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 10,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004851 · form4-02202025_090211.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,946 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 16, 2024 Filed May 17, 2024 16:21 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 20,651 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0001415889-24-013504 · form4-05172024_080555.xml · derivative · entry 9 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,349 Underlying: Class A Common Stock · 20,651 shares Expires 2033-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48 of the total stock option vests and becomes exercisable monthly on the same day of each month following February 15, 2023, subject to continuous service of the Reporting Person on each vesting date. Read SEC document |
| May 16, 2024 Filed May 17, 2024 16:21 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,500 | $43.03 | $107,572.50 |
DisclosureSEC source: 0001415889-24-013504 · form4-05172024_080555.xml · nonDerivative · entry 7 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,206 F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.01 to $43.08, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 16:21 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 2,500 | $7.87 | $19,675.00 |
DisclosureSEC source: 0001415889-24-013504 · form4-05172024_080555.xml · nonDerivative · entry 6 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2024 Filed May 17, 2024 16:21 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 18,151 | $42.22 | $766,317.07 |
DisclosureSEC source: 0001415889-24-013504 · form4-05172024_080555.xml · nonDerivative · entry 5 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,206 F1 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.86, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2024 Filed May 17, 2024 16:21 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 18,151 | $7.87 | $142,848.37 |
DisclosureSEC source: 0001415889-24-013504 · form4-05172024_080555.xml · nonDerivative · entry 4 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2024 Filed May 17, 2024 16:21 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 8,221 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001415889-24-013504 · form4-05172024_080555.xml · derivative · entry 8 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,589 Underlying: Class A Common Stock · 8,221 shares Expires 2031-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| May 15, 2024 Filed May 17, 2024 16:21 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,965 | $42.68 | $83,866.20 |
DisclosureSEC source: 0001415889-24-013504 · form4-05172024_080555.xml · nonDerivative · entry 3 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,206 Read SEC document |
| May 15, 2024 Filed May 17, 2024 16:21 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 8,221 | $42.17 | $346,679.57 |
DisclosureSEC source: 0001415889-24-013504 · form4-05172024_080555.xml · nonDerivative · entry 2 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,171 Read SEC document |
| May 15, 2024 Filed May 17, 2024 16:21 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 8,221 | $3.94 | $32,387.45 |
DisclosureSEC source: 0001415889-24-013504 · form4-05172024_080555.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 16:02 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 5,714 | $40.00 | $228,560.00 |
DisclosureSEC source: 0001415889-24-010753 · form4-04122024_080416.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,171 F1 · balance_after: Includes 1,831 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2024. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 16:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 81,250 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001415889-24-001518 · form4-01182024_090112.xml · derivative · entry 2 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,250 Underlying: Class A Common Stock · 81,250 shares Expires 2034-01-15 F3 · derivative.exercise_date: 1/48 of the shares subject to the stock option will vest and become exercisable on February 16, 2024, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 16:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001518 · form4-01182024_090112.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, FINANCE, CHIEF ACCT OFFCR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,054 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service through each vesting date. F2 · balance_after: Includes 2,500 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on September 13, 2023. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001209191-23-041521 · doc4.xml · derivative · entry 2 Young Joseph R · CIK 0001861684 · SVP, Finance, Chief Acct Offcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,810 Underlying: Class A Common Stock · 10,000 shares Expires 2031-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 10,000 | $3.94 | $39,396.00 |
DisclosureSEC source: 0001209191-23-041521 · doc4.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, Finance, Chief Acct Offcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:14 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0001209191-23-010554 · doc4.xml · derivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, Finance, Chief Acct Offcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Class A Common Stock · 90,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: 1/48 of the total stock option will vest and become exercisable monthly on the same day of each month following February 15, 2023, subject to continuous service of the Reporting Person on each vesting date. Read SEC document |
| February 06, 2023 Filed Feb 17, 2023 16:19 UTC Amendment | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 5,714 | $7.00 | $39,998.00 |
DisclosureSEC source: 0001209191-23-010595 · doc4a.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, Finance, Chief Acct Offcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,679 F1 · date: The reporting person's original Form 4 contained a typographical error on the transaction date. F2 · shares: Shares purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 6, 2023. The purchase price is the offering price. F3 · balance_after: Includes 817 shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 16:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047167 · doc4.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, Finance, Chief Acct Offcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,148 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under Issuer's 2021 Equity Incentive Plan. One-third of the RSUs vest on August 20, 2023, rounded to the nearest whole share, and the remaining RSUs vest on August 20, 2024, subject to the Reporting Person's continuous service through each vesting date. F2 · balance_after: Includes 1,148 shares acquired under the Issuer's Employee Stock Purchase Plan on March 11, 2022. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 16:10 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 36,729 | $0.00 Strike: $20.94 | $0.00 |
DisclosureSEC source: 0001209191-22-011220 · doc4.xml · derivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, Finance, Chief Acct Offcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,729 Underlying: Class A Common Stock · 36,729 shares Expires 2032-02-15 F1 · derivative.exercise_date: 1/48 of the total stock option will vest and become exercisable monthly on the same day of each month following February 16, 2022, subject to continuous service of the Reporting Person on each vesting date. Read SEC document |
| February 06, 2022 Filed Feb 8, 2023 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 5,714 | $7.00 | $39,998.00 |
DisclosureSEC source: 0001209191-23-007770 · doc4.xml · nonDerivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, Finance, Chief Acct Offcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,679 F1 · shares: Shares purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 6, 2023. The purchase price is the offering price. F2 · balance_after: Includes 817 shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:30 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 13,722 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033332 · doc4.xml · derivative · entry 1 Young Joseph R · CIK 0001861684 · SVP, Finance, Chief Acct Offcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,722 Underlying: Class A Common Stock · 13,722 shares Expires 2031-05-12 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 13, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.